Hemorrhagic fever viruses as biological weapons: Medical and public health management

JAMA

Volumn 287, Issue 18, 2002, Pages 2391-2405

  Borio, Luciana ^a,b   Inglesby, Thomas ^a   Peters, C J ^e   Schmaljohn, Alan L ^f   Hughes, James M ^g   Jahrling, Peter B ^f   Ksiazek, Thomas ^g   Johnson, Karl M ^h   Meyerhoff, Andrea ⁱ   O'Toole, Tara ^a   Ascher, Michael S ^k   Bartlett, John ^a   Breman, Joel G ^c   Eitzen, Edward M ^f   Hamburg, Margaret ^l   Hauer, Jerry ^k   Henderson, D A ^a   Johnson, Richard T ^a   Kwik, Gigi ^a   Layton, Marci ^m   Lillibridge, Scott ^k   Nabel, Gary J ^d   Osterholm, Michael T ⁿ   Perl, Trish M ^a   Russell, Philip ^k   Tonat, Kevin ^j   more..

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^f UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^g NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^h UNIVERSITY OF NEW MEXICO   (United States)

ⁱ CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^j U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^k Department of Health and Human Services   (United States)

^l University of Minnesota ^*  (United States)

^m NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

ⁿ UNIVERSITY OF MINNESOTA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

RIBAVIRIN;

ARENAVIRUS; BIOLOGICAL WARFARE; BUNYAVIRUS; CLINICAL FEATURE; EVIDENCE BASED MEDICINE; FILOVIRIDAE; FIRST AID; FLAVIVIRUS; HEMORRHAGIC FEVER; HUMAN; MEDLINE; MILITARY SERVICE; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; VIRUS TRANSMISSION;

EID: 0037042244     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.287.18.2391     Document Type: Review

References (140)

1. Anthrax as a biological weapon
2. Smallpox as a biological weapon
3. Plague as a biological weapon
4. Botulinum toxin as a biological weapon
5. Tularemia as a biological weapon
6. Fatal illnesses associated with a new world arena virus - California, 1999-2000
7. Patients infected with high-hazard viruses
8. Dengue and other emerging flaviviruses
9. Viral hemorrhagic fevers
10. Epidemiologic and clinical features of Crimean-Congo hemorrhagic fever in southern Africa
11. Spectrum of hantavirus infection: Hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome
12. The effect of the methods for producing an experimental Marburg virus infection on the characteristics of the course of the disease in green monkeys
13. Lethal experimental infections of rhesus monkeys by aerosolized Ebola virus
14. Certain pathogenetic characteristics of a disease in monkeys in infected with the Marburg virus by an airborne route
15. Effect of environmental factors on aerosol-induced Lassa virus infection
16. Aerosol infection of rhesus macaques with Junin virus
17. Epidemiology of hemorrhagic fever viruses
18. Marburg and Ebola virus infections in laboratory nonhuman primates: A literature review
19. Ebola haemorrhagic fever in Zaire, 1976
20. A case of Ebola virus infection
21. Marburg agent disease
22. Lethal experimental infection of rhesus monkeys with Ebola-Zaire (Mayinga) virus by the oral and conjunctival route of exposure
23. Ebola haemorrhagic fever - A review
24. A novel immunohistochemical assay for the detection of Ebola virus in skin
25. Transmission of Ebola hemorrhagic fever: A study of risk factors in family members, Kikwit, Democratic Republic of the Congo, 1995
26. The reemergence of Ebola hemorrhagic fever, Democratic Republic of the Congo, 1995
27. Ebola outbreak in Kikwit, Democratic Republic of the Congo: Discovery and control measures
28. Perspectives in fatal epidemics
29. The pathogenesis and epidemiology of the "Marburg-virus" infection
30. Ebola hemorrhagic fever, Kikwit, Democratic Republic of the Congo, 1995: Risk factors for patients without a reported exposure
31. Outbreak of Ebola hemorrhagic fever, Uganda, August 2000 - January 2001
32. Transmission of Ebola virus (Zaire strain) to uninfected control monkeys in a biocontainment laboratory
33. Combined simian hemorrhagic fever and Ebola virus infection in cynomolgus monkeys
34. The Marburg virus outbreak of 1967 and subsequent episodes
35. Outbreak of Marburg virus disease in Johannesburg
36. Ebola virus disease in southern Sudan
37. Human infection due to Ebola virus, subtype Cote d'lvoire
38. Unexpected Ebola virus in a tertiary setting
39. Organization of patient care during the Ebola hemorrhagic fever epidemic in Kikwit, Democratic Republic of the Congo, 1995
40. Clinical, virologic, and immunologic follow-up of convalescent Ebola hemorrhagic fever patients and their household contacts, Kikwit, Democratic Republic of the Congo
41. Persistence and genetic stability of Ebola virus during the outbreak in Kikwit, Democratic Republic of the Congo, 1995
42. Chronic infection of rodents by Machupo virus
43. Isolation of Machupo virus from wild rodent Calomys callosus
44. Lassa fever: Epidemiological aspects of the 1970 epidemic, Jos, Nigeria
45. Lassa fever: A study of 23 hospital cases
46. A hospital epidemic of Lassa fever in Zorzor, Liberia, March April 1972
47. Hemorrhagic fever in Cochabamba, Bolivia, 1971
48. Lassa fever: Response to an imported case
49. A case of Lassa fever: Experience at St Thomas's Hospital
50. Treatment of Bolivian hemorrhagic fever with intravenous ribavirin
51. Lassa fever, a new virus disease of man from West Africa, III: Isolation and characterization of the virus
52. Contagio interhumano e infeccion clinical con virus Junin en matrimonios residentes en el area endemica de fiebre hemorragica Argentina
53. Rift Valley fever
54. Analytical study of a Rift Valley fever epidemic
55. Rift Valley fever: Accidental infections among laboratory workers
56. The Rift Valley fever epizootic in Egypt 1977-78, I: Description of the epizootic and virological studies
57. Rift valley fever
58. Susceptibility of selected strains of Australian mosquitoes (Diptera: Culicidae) to Rift Valley fever virus
59. Vector potential of selected North American mosquito species for Rift Valley fever virus
60. Yellow fever: An update
61. Viral infections in laboratory personnel
62. Hemorrhagic fever virus induced changes in hemostasis and vascular biology
63. The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis
64. An analysis of features of pathogenesis in 2 animal models of Ebola virus infection
65. Replication of Marburg virus in human endothelial cells
66. Protection against a pathogenic strain of Junin virus by mucosal infection with an attenuated strain
67. Pathogenesis of viral hemorrhagic fevers
68. Lassa virus infection of rhesus monkeys
69. A plasma inhibitor of platelet aggregation in patients with Argentine hemorrhagic fever
70. Importance of dose of neutralising antibodies in treatment of Argentine haemorrhagic fever with immune plasma
71. Hemostatic derangement produced by Rift Valley fever virus in rhesus monkeys
72. Experimental Rift Valley fever in rhesus macaques
73. Prevention of Rift Valley fever in rhesus monkeys with interferon-alpha
74. Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues
75. Pathological findings in 3 fatal human cases of Kyasanur Forest disease
76. Ebola haemorrhagic fever in Sudan, 1976
77. Marburg virus disease in Kenya
78. Endemic Lassa fever in Liberia, I: Clinical and epidemiological aspects at Curran Lutheran Hospital, Zorzor, Liberia
79. Lassa fever in Panguma Hospital, Sierra Leone, 1973-6
80. Clinical presentation of Lassa fever cases during the hospital epidemic at Zorzor, Liberia, March-April 1972
81. A case-control study of the clinical diagnosis and course of Lassa fever
82. Re-emergence of Bolivian hemorrhagic fever
83. Haemorrhagic fevers of Africa: An account of 2 recent outbreaks
84. An epizootic of Rift Valley fever in Egypt in 1997
85. Epidemic Rift Valley fever in Egypt
86. Clinical studies on Rift Valley fever, I: Acute febrile and hemorrhagic-like diseases
87. Flaviviruses
88. Clinical study of 100 cases of Kyasanur Forest disease with clinicopathological correlation
89. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: Clinical observations in 103 patients
90. Lassa fever, a new virus disease of man from West Africa, I: Clinical description and pathological findings
91. Lassa fever in the Eastern Province of Sierra Leone, 1970-1972, II: Clinical observations and virological studies on selected hospital cases
92. Uveal involvement in Marburg virus disease
93. Clinical recognition and management of patients exposed to biological warfare agents
94. Lassa fever: Effective therapy with ribavirin
95. Antiviral treatment of Argentine hemorrhagic fever
96. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug
97. Update: Management of patients with suspected viral hemorrhagic fever - United States
98. Clinical features of Lassa fever in Liberia
99. Intravenous ribavirin therapy for adenovirus pneumonia
100. Safety, efficacy, and pharmacokinetics of interferon alfa-2b plus ribavirin in children with chronic hepatitis C
101. Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients
102. On an infectious disease transmitted by Cercopithecus aethiops ("green monkey disease")
103. Lassa fever, a new virus disease of man from West Africa, II: Report of a laboratory-acquired infection treated with plasma from a person recently recovered from the disease
104. The use of Lassa fever convalescent plasma in Nigeria
105. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome
106. Lassa immune serum
107. In vivo enhancement of dengue virus infection in rhesus monkeys by passively transferred antibody
108. Effect of ribavirin and tributylribavirin on argentine hemorrhagic fever (Junin virus) in guinea pigs
109. Additive effect of neutralizing antibody and antiviral drug treatment in preventing virus escape and persistence
110. Shortage of vaccines during a yellow fever outbreak in Guinea
111. Guideline for isolation precautions in hospitals
112. Personal respiratory protection against Mycobacterium tuberculosis
113. The effect of high-efficiency particulate air respirator design on occupational health
114. Management of a Sabia virus-infected patients in a US hospital
115. Tuberculosis risk in funeral home employees
116. Management of patients with suspected viral hemorrhagic fever
117. Candid No. 1 Argentine hemorrhagic fever vaccine protects against lethal Junin virus challenge in rhesus macaques
118. Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever
119. Rift Valley fever virus vaccine trial
120. Immunogenicity of an inactivated Rift Valley fever vaccine in humans
121. Field evaluation of formalin inactivated Kyasanur forest disease virus tissue culture vaccine in 3 districts of Karnataka state
122. Development of a preventive vaccine for Ebola virus infection in primates
123. DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge
124. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates
125. Effective vaccine for Lassa fever
126. Passive transfer of antibodies protects immunocompetent and immunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication